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Abstract: Invertebrates account for more than 89% of all extant organisms in the marine environment,
represented by over 174,600 species (recorded to date). Such diversity is mirrored in (or more likely
increased by) the microbial symbionts associated with this group and in the marine natural products
(or MNPs) that they produce. Since the early 1950s over 20,000 MNPs have been discovered, including
compounds produced by symbiotic bacteria, and the chemical diversity of compounds produced
from marine sources has led to them being referred to as "blue gold" in the search for new drugs.
For example, 80% of novel antibiotics stemming from the marine environment have come from
Actinomycetes, many of which can be found associated with marine sponges, and compounds with
anti-tumorigenic and anti-diabetic potential have also been isolated from marine symbionts. In fact,
it has been estimated that marine sources formed the basis of over 50% of FDA-approved drugs
between 1981 and 2002. In this review, we explore the diversity of marine microbial symbionts by
examining their use as the producers of novel pharmaceutical actives, together with a discussion of
the opportunities and constraints offered by “blue gold” drug discovery.
Keywords: marine natural products; microbial symbionts; marine invertebrates; pharmaceuticals;
“blue gold”
1. Introduction
The term symbiosis was first defined by the German surgeon Anton de Bary in 1878 as “the living
together of differently named organisms” [1]. In nature, symbioses are frequently represented by a
microorganism living with a host—such as an animal, plant, or another microorganism [2]. Symbiotic
interactions can be parasitic, commensal, or mutualistic [3,4]; the latter being defined by de Bary as
a system “in which there is a reciprocal benefit for the symbionts” [1]. These mutually beneficial
living arrangements are common, and have frequently evolved to be essential to the livelihood of both
partners—in the absence of their microbial symbionts, most animals and plants could not survive [2].
Due to co-evolution with their specific host, microbial symbionts express a variety of uniquely
tailored biochemical traits, making them a highly productive source of secondary metabolites with
well-defined architectures and medically and commercially attractive bioactivities [5]. As these
compounds evolved to interact efficiently with a co-evolving biological target they are often structurally
unique; indeed the Dictionary of Natural Products states that over 40% of these chemical scaffolds
occupy a chemical space not represented by synthetic compounds [6]. Furthermore, they tend to be
complex and with well-defined spatial orientations, and as this unique diversity is coupled with the
occupation of a biologically relevant chemical space, these natural products are an excellent starting
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point for drug discovery [7]. Of the 1184 new compounds approved between the years 1981–2006 as
drugs for the treatment of human diseases the majority were derived from natural products and only
30% were of synthetic origin [8]. Along with their clinical advantages, drugs derived from natural
products are in high demand. In 2000 approximately half of the 20 best-selling non-protein drugs were
related to natural products [9] and the demand for such products is increasing; for example, it has been
estimated that by 2020 around $115 billion will be spent globally on herbal supplements alone [10],
and in 2014, consumers spent around $6.4 billion on herbal supplements in the United States—a 6.8%
increase over 2013 and the 11th consecutive year of increased market growth [11]. The term “natural
product” is clearly embraced by consumers [12].
Arguably one of the most productive branches of natural pharmaceutical development is that of
the marine natural products (MNPs), known as “blue gold” drug discovery, the development of novel
actives from the marine environment [7]. A comparative analysis by Kong et al. in 2010 showed that
MNPs have greater chemical novelty compared to their terrestrial counterparts [13], and many of these
compounds have advanced to clinical trials and pharmaceutical products [5,14,15]. Since 1965 over
20,000 MNPs have been described [16], that have formed the basis of over 50% of FDA-approved drugs
in the period 1981–2002 [17]. In 2015 alone 1340 new MNPs have been published in 429 papers [14]; as
our oceans cover 71% of the earth’s surface, yet remain 95% unknown [18], the potential for further
drug discovery is immense.
At the time of writing, more than 30,607 articles focusing on MNPs have been uploaded to
MarinLit, a database of MNP literature [16], many of which relate to MNPs produced by marine
invertebrates, most notably marine sponges and corals [19–21]. Marine invertebrates account for
over 89% of all extant marine animals, comprising of over 174,600 species [22]; this diversity is not
only found between the animals themselves, but also between the symbiotic microorganisms that
comprise the entire holobiont [23–29]. More than 47 bacterial phyla have been sequenced from sponges
alone [30], and high throughput sequencing of the 16S rRNA gene has unveiled an incredible diversity
of symbiotic bacteria within the sponge body [31,32].
It is now thought that many of the MNPs with pharmacological activity that have been isolated
from marine invertebrates are likely to be produced, not by the animals themselves, but rather by
their symbiotic microbiota [8,33–35]; for example, 80% of antibiotics from marine sources come from
Actinomyces spp., several species of which are associated with marine sponges [36–38]. Given that
endosymbiotic bacteria make up to 50–60% of the dry weight of a sponge, there are certain to be many
marine symbionts producing as yet undiscovered bio-active compounds [39].
This review showcases the diversity of marine invertebrate symbionts via notable examples of the
pharmaceutical MNPs they produce. A brief discussion of the opportunities and constraints inherent
in such drug discovery is also included.
2. β-glucosidase Inhibitors: Compounds with Anti-Diabetic Potential
In 2013 over 382 million people were estimated to be suffering from diabetes mellitus (commonly
called diabetes), by 2030 this figure is estimated to rise to 500 million [40]; in 2015 diabetes was listed
as number five in the top causes of death by The World Health Organisation (WHO) [41].
The increasing prevalence of diabetes, coupled with the seriousness of the disease, has resulted in
an extensive search for novel anti-diabetics, some searches of which have focused within the marine
biome. We refer readers to a recent review by Lauritano and Ianora [42], who focus on the recent
advances in the discovery of marine organisms with such anti-diabetic properties. Targets examined in
anti-diabetic drug screening include specific enzymes involved in sugar metabolism, proteins involved
in the signaling of insulin responsive tissue, molecules able to protect pancreatic β cells (in type-1
diabetes studies), and molecules implicated in diabetic retinopathy—one of the most common and
debilitating side-effects of diabetes [42]. In 2013 Pandey et al. screened 181 bacteria from marine
sediment and sponges forβ-glucosidase inhibitors; these compounds are likely to act on the glucosidase
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enzymes of other microorganisms, providing a competitive edge to the microbe producing them in the
crowded ecological niche of the marine environment [43].
Glucosidase enzymes catalyze the cleavage of glycosidic bonds involving α- and β-linked
glucose units, or the bonds between sugars and a non-carbohydrate aglycone moiety, and as such
are involved in glucose production [43,44]. The classic β-glucosidase inhibitor, nojirimycin from
Streptomyces roseochromogenes (Strain R-468) and Streptomyces lavendulae (Strain SF-425), and its
derivatives are at present extensively used in the treatment of type II diabetes (Figure 1) [45–47].
The screening process in 2013 found 41 bacteria producing β-glucosidase inhibitors, of
which 34% were associated with marine sponges—6 out of 41 (14.6%) isolates from the sponge
Sarcotragus fasciculatus and 8 out of 30 (26.6%) from the sponge Aka coralliphaga produced the
compounds. These corresponded to 3 and 7 different species respectively, of which 2 and 6 were
identified to the species level (Table 1) [43].
Table 1. Select MNPs of pharmaceutical significance isolated from symbionts of marine invertebrates.
Microbial Species Host Location Compound/s Compound Activity
Halomonas sulfidaeris and
Bacillus tequilensis
Sponge
Sarcotragus fasciculatus Bay of Bengal
β-glucosidase
inhibitors Anti-diabetic potential [43]
Bacillus sp., Leucobacter
chromiiresistens, Planococcus
rifitoensis, Bacillus
stratosphericus, Bacillus
amyloliquefaciens subsp.
amyloliquefaciens, and
Streptomyces rangoonensis
Sponge Aka coralliphaga Bay of Bengal β-glucosidaseinhibitors Anti-diabetic potential [43]
Candidatus Endoecteinascidia
frumentensis
Tunicate Ecteinascidia
turbinata Carribean Sea
Yondelis®
(ecteinascidin 743/
trabectedin)
Anti-tumerogenic
drug [48]
Synechococcus spongiarum SpongeSmenospongia aurea Bahamas
Smenamide A/B and
smenothiazoles A/B
Anti-tumerogenic
activity [49,50]
Unknown: Various species
suspected including
a-proteobacteria
and Actinomycetes
Sponge Genera
Petrosiidae, Ircinia,
Amphimedon, Haliclona,
Xestospongia, Pachypellina,
and Prianos
Global Manzamine-typealkaloids
Antitumor, antibacterial,
cytotoxic, and
immunestimulatory
activities [51–54]
Bacterial genera Micrococccus
and Kocuria
Sponge genera
Xestospongia Florida Keys Kocurin
Thiazolyl peptide
antibiotic [55,56]
Pseudoalteromonas piscicida SpongeHymeniacidon perleve Eastern China Sea
Norharman
(β-carboline alkaloid) Anti-microbial [57]
Bacillus subtilis (Strain A184) SpongeAplysina aerophoba Mediterran Lipoproteins Anti-microbial [58]
Cochliobolus lunatus
(Strain TA26- 46)
Sea anemone
Palythoa haddoni South China Sea
Resorcylic acid
lactones Anti-fungal [59]
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3. Yondelis®, Smenamides, and Smenothiazoles: Compounds with Anti-Tumorigenic Potential
In a US National Cancer Institute preclinical cytotoxicity screening program over 1% of MNPs
showed anti-tumor properties; this is 10 times greater than their estimate for natural products
of terrestrial origin, at only 0.1% [71]. This is potentially reflected in the number of successful
anti-tumorigenic compounds is lat d rom marine inve tebrat s that hav m de it to market. The first
of these, a sy thetic a alogue of a C-nucleoside from the sponge Tethya crypt , was ara-C (4-cytarabine,
Alexan®,Udicil®), approved in 1969 it is still used today to treat acute myelocytic leukemia and
non-Hodgkin’s lymphoma [72–74]. Following from this initial discovery, a variety of other anti-cancer
drugs from marine invertebrates have been developed. These include for example; Halaven® (eribulin),
used to treat metastatic breast cancer [75] and developed from the metabolite halichondrin B produced
by the sponge Halichondria okadai [76,77], and ADCETRIS® (brentuximab vedotin, SGN-35) used for the
treatment of Hodgkin lymphoma and anaplastic large cell lymphoma [78], and developed via antibody
chimerisation through the addition of a dipeptide linker to the potent antitubulin agent dolastatin 10
from the sea hare Dolabella auricularia [79,80].
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Illustrative of the importance of symbionts to marine drug discovery, some of these
anti-tumorigenic compounds are now suspected to originate from the marine invertebrates symbiotic
bacteria, rather than the host itself [8,19,34]. For example, this is true of the anti-tumorigenic drug
Yondelis® (Figrue 1), approved in 2007 for the treatment of ovarian cancer and tissue sarcomas [62].
In the 1950s the American National Cancer Institute began a comprehensive program of screening
marine material for possible anti-cancer properties, as part of this program an extract from the
tunicate Ecteinascidia turbinata was found to have anticancer activity. Eventually, the structure of
one of the active compounds within this extract, ecteinascidin 743 (ET-743), was determined by KL
Rinehart [81]. A synthetic synthesis pathway was developed [82], leading to the drug, trabectedin,
this active compound was then used successfully in clinical trials and marketed as Yondelis® [62,63].
Interestingly, ET-743 has since been shown, not to derive from E. turbinata itself, but rather from
one of its symbionts, a γ-proteobacterium Candidatus Endoecteinascidia frumentensis. Firstly, the real
origin of the active compound was implied indirectly, by observation that E. frumentensis was the most
prevalent member from the tunicate microbial consortium at all collection sites in the Mediterranean
and Caribbean seas [83,84]. However, more recently, Rath et al. employed novel techniques involving
Meta-Omic characterization of the microbial consortium associated with E. turbinata and revealed
25 genes that comprise the core of the ET-743 biosynthetic pathway, and resulting sequence analysis
strongly suggested that E. frumentensis is in fact the producer of ET-743 (Table 1) [48].
Similarly, the compounds smenamide A and B, which show potent cytotoxic activity at nanomolar
levels on lung cancer Calu-1 cells, are likely to originate from a symbiont of another marine invertebrate.
These compounds were isolated as a result of a detailed study into the secondary metabolites contained
within the lipophilic extract of the sponge Smenospongia aurea. Samples were collected along the coast
of Little Inagua (Bahamas Islands) as part of a broad screening program conducted by the NeaNat
research group at the Università degli Studi di Napoli Federico II in Naples, Italy. This in depth
examination led to the elucidation of structures of the two smenamides, and these smenamides
appeared to be the products of cyanobacterial metabolism. Indeed further 16S rRNA metagenomic
analysis detected Synechococcus spongiarum as the only cyanobacterium present in S. aurea and thus the
likely producer of these anti-tumorigenic compounds [50]. Further study on the same sponge species
revealed two further anti-tumorigenic compounds, this time with selectivity for ovarian cancer cells.
These compounds, the smenothiazoles A and B (Figure 1), also contained structural motifs that are
present in cyanobacterial metabolites, and as such likely also originate from S. spongiarum (Table 1) [49].
4. Manzamine, Kocurin, Norharman, Lipopeptides, and Lactones: Compounds with
Anti-Pathogenic Potential
Marine microorganisms live in highly competitive environments, selecting for the evolution
of various chemical protection strategies, such as the production of anti-microbial, anti-fungal, or
anti-viral secondary metabolites [85]. Those microbes which have formed symbiotic relationships with
a marine invertebrate, like a sponge or coral, have often developed further secondary metabolites,
which also protect their hosts from pathogens [86,87]. This combination of self and host protection has
selected for a huge range of secondary metabolites isolated from marine symbionts that are reported
to have anti-microbial or anti-pathogenic properties [8,19].
Manzamines, produced by actinomycete Micromonospora species for example, are associated with
several sponge genera, and have significant potential as anti-pathogenic compounds as they have been
shown to have in vitro and in vivo activity against the malaria parasite Plasmodium berghei [51,66,88–92].
Furthermore, they are also active against Mycobacterium tuberculosis (now responsible for more
deaths worldwide than HIV) and Leishmania, as well as having insecticidal properties [51,66,88–92].
The importance of manazamines was recognized as early as 1986 when Sakai and co-workers first
reported manzamine A from the Okinawan sponge of the genus Haliclona (Figure 1) [66]. Since this
first report, 40 more manzamine-type alkaloids have been reported from several different sponge
genera (Table 1) [51–54].
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Also from sponge-associated actinomycete bacteria the molecule kocurin (Figure 1), a new
member of the thiazolyl peptide family of antibiotics, has been isolated from strains in the family
Microccocaceae [19]. In their 2013 study Palomo et al. isolated 44 Microccocaceae strains from sponges
collected in the Florida Keys, and off the coast of Fort Lauderdale and Maryland in the USA. Based on
16S rRNA gene sequences, 15 strains were found to belong to the genera Micrococccus and 29 to the
genera Kocuria. All Micrococcus strains were found to be of the same species, M. yunnanensis, whereas
Kocuria strains belonged to 7 different species: K. flava, K. marina, K. palustris, K. rhizophila, K. rosea,
K. sediminis and K. turfanensis [55,56]. Following identification, these strains were screened for the
presence of secondary metabolite genes, then grown in nutritional arrays; finally, strains were analyzed
for the production of antibacterial and antifungal activities in whole-cell agar-based growth inhibition
assays. These assays targetted clinically relevant strains of Bacillus subtilis (MB964), and the pathogens;
methicillin-resistant Staphylococcus aureus (MRSA) (MB5393), Acinetobacter baumannii (MB5973) and the
yeast Candida albicans (MY1055). Three isolates were shown to produce a new anti-MRSA bioactive
compound, Kocuria marina F-276,310, Kocuria palustris F-276,345, and Micrococcus yunnanensis F-256,446,
and this compound was identified as kocurin (Table 1) [55]. In the same study, the group also confirmed
that two related strains of Microccocaceae, corresponding to the Arthrobacter strains; R-7513 and R-7914,
that they had previously isolated from Antarctic microbial mats also produced kocurin [55,56,93].
The Phylum Proteobacteria is the second largest group producing bioactive metabolites
associated with sponges after the Actinobacteria (discussed above) [19]. For example, norharman
(a β-carboline alkaloid) is an anti-microbial metabolite (Figure 1), isolated from strains of the bacteria
Pseudoalteromonas piscicida which have been shown to be associated with the sponge Hymeniacidon
perleve [57]. Out of 29 strains isolated during a study by Zheng et al. in 2005, eight strains inhibited
the growth of various other pathogenic microorganisms. P. piscicida strain NJ6-3-1 showed a wide
antimicrobial spectrum, being active against Bacillus subtilis (CMCC 63003), Staphylococcus aureus
(CMCC 26001), Escherichia coli (CMCC 44102), and Agrobacterium tumefaciens (AS 1.1416). Furthermore,
NJ6-3-1 also displayed antifungal activity against the yeast Saccharomyces cerevisiae ACCC 2.1882.
The major antimicrobial metabolite from this strain was identified as norharman, and was actually
previously isolated from Indonesian sponges by Rao et al. two years earlier (Table 1) [51,57].
Bacteria from other phyla, such as Firmicutes for example, have also been shown to produce
anti-pathogenic compounds, especially strains of Bacillus [19]. The Mediterranean sponge Aplysina
aerophoba contains brominated metabolites with strong antimicrobial activity [94], thus in 2003
Pabel et al. reasoned that as symbiotic bacteria residing in A. aerophoba must be resistant to
these bioactive metabolites, they may be capable of producing similar antimicrobial compounds
themselves. They discovered 5 Bacillus isolates with pronounced antifungal and antimicrobial
activities. One particular strain of Bacillus subtilis (A184), was shown to produce anti-microbial
lipoproteins namely iturins, fengycins and surfactins [58]. This strain had antimicrobial activity against
Staphylococcus aureus, Escherichia coli, Vibrio species SB1 (a marine isolate), Clavibacter michiganensis,
Bacillus megaterium, Proteus vulgaris and Agrobacterium tumefaciens, and had antifungal activity against
the mold Paecilomyces variotii and the yeast Candida albicans. Of particular note, was the activity
of strain A184 against the multi-drug resistant Staphylococcus aureus (Strain A134—is resistant to
ciprofloxacin, clindamycin, erythromycin, gentamicin, oxacillin, penicillin G) and the multi-drug
resistant Staphylococcus epidermidis (Strain RP62A—which is resistant to clindamycin, erythromycin,
gentamicin, oxacillin, penicillin G, and trimethoprim) (Table 1) [58].
In addition to bacteria, anti-pathogenic compounds are also made by symbiotic fungi associated
with various marine invertebrates [8]. For example, Cochliobolus lunatus (strain TA26- 46), isolated
by Liu et al. in 2014 from the sea anemone Palythoa haddoni was found to produce resorcylic acid
lactones, compounds that had previously been shown to have activity against pathogenic fungi [59].
Of eleven compounds, an isolated one, zeaenol (Figure 1), exhibited excellent fungicidal activity
against the crop-pathogenic fungi Plasmopara viticola and Phytophthora infestans in a whole-plant assay
(Table 1) [59].
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5. Constraints and Future Prospects
This review highlights but a few of the compounds produced by microbial symbionts that have
potential as pharmaceuticals [8,73,95,96]. For example, we draw readers to the recent excellent review
by Zhang et al. which describes in detail over 107 cytotoxic agents which have been discovered from
1955 to 2016 that are metabolized by marine sponge-derived symbionts alone [95] (including terpenes,
alkaloids, peptides, aromatics, lactones, and steroids, amongst others). Several other recent detailed
reviews are also available which provide information on the many compounds discovered from marine
invertebrates, including cytotoxic, anti-microbial, anti-protozoal, anti-leishmanial, anti-trypanosomal
and anti-inflammatory compounds, compounds which may actually originate from the host-associated
microbes and not the invertebrates themselves [8,19,20,48,97–106].
In addition, the screening of such symbiotic microbes from marine invertebrates is only beginning
to scratch the surface with regard to finding cures and treatments for many diseases. The screening
process carried out by Pandey et al. for β-glucosidase inhibitors as anti-diabetics examined only two
sponge species, with over 9000 described members of Porifera, the possibilities are staggering [43].
Indeed, other studies are also starting to show other anti-diabetic compounds from both sponges and
even corals [42].
It should be noted here, that despite the clear benefits to MNP discovery, there are certain
constraints faced by researchers in the hunt for “blue gold”; the principle one being that many
symbionts are currently unculturable away from their respective hosts. In fact it is estimated that as
many as 99% are considered “unculturable” [107], thus making the screening and mass-production of
any pharmaceuticals they produce very difficult using common culturing methods [85]. One seemingly
simple solution to this problem is to culture the host organism along with the symbiont, in a manner
that maximises secondary metabolite production by the microbe [21,108,109]. However, this adds an
extra level of complexity to the culturing procedure, having to accommodate the needs of an entire
complex holobiont. The conditions used would have to mimic the exact natural conditions of the host
marine invertebrate to ensure it was in a state that promoted growth of the desired symbiont, as it has
been shown that the microbial composition of certain marine invertebrates, like corals for example
can vary significantly under ex-situ culturing conditions [110,111]. That said, recent advances in the
design of new culture media, the development of nature-mimicking culture systems, the optimization
of growth conditions in bioreactors, the development of efficient automated harvesting protocols for
organisms with biotechnological potential, and the invention of different ways of co-cultivation and
mixed culturing [8,112] appear to be addressing these issues, at least to some degree.
Alternatively, the advances occurring at a rapid rate in the fields of bioinformatics and molecular
biology may offer the potential to clone a gene of interest into a heterologous system, then
express the desired product in an easier-to-culture host (effectively removing the issues described
above). Various antimicrobial MNPs have indeed been discovered by using the approach of cloning
metagenomic DNA (the entire DNA from an environmental niche) into such a heterologous host, a
process known as functional metagenomics (reviewed in Trindade et al. and references therein) [113].
Although, such heterologous hosts may in turn prove incompatible in terms of their expression of
heterologous DNA, and toxicity of any expressed products [8] the potential of functional metagenomics
in gaining access to a vast range of products produced by as yet uncultivable microbes remains
attractive to researchers.
6. Conclusions
To conclude, given the sheer number of marine invertebrates present in the ocean, and the even
greater number of associated microbes on and within each host, it is without doubt that there are
many more MNPs to be discovered—offering significant opportunity to treat complex diseases that
are increasing in prevalence, such as multi-drug resistant infections, neglected tropical diseases, cancer,
and diabetes. Current obstacles to turning these actives into useable, cost-effective drugs are being
overcome due to intensive efforts into optimising culturing techniques and chemical synthesis, this
Diversity 2017, 9, 49 8 of 13
work, coupled with advances in metabolomics and bio-informatics to identify compound-producing
species—means that symbionts are providing a promising future for “blue gold” drug discovery.
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